

6 October 2026

dorsaVi Raises A\$3.0 Million for Humanoid Robotics Strategy and RRAM Chip Tape-Out

Funding commitments received to expand dorsaVi's movement data and bespoke capture capabilities for humanoid robotics, and advance its neuromorphic and RRAM development programs.

Key Highlights:

- Firm commitments received to raise \$3 million (before costs) via a Placement to a restricted group of high-net-worth investors at \$0.022 per Share.
- Strong demand received from both new and existing sophisticated and professional investors following recent progress across all dorsaVi's three connected verticals.
- Proceeds will expand dorsaVi's clinical-grade human movement data library and bespoke data-capture capability (wearable sensors and Video AI) for humanoid robotics developers.
- Proceeds will also advance dorsaVi's licensed neuromorphic IP and RRAM development program and support targeted exploration of Physical AI applications in smart-soldier systems, aerial drone and autonomous underwater vehicles.
- The first RRAM-CMOS validation chip has completed front-end and middle-of-line fabrication on TSMC's CMOS process. The wafers now advance into proprietary RRAM integration, generating the silicon data designed to guide dorsaVi's planned progression toward future 22-nm RRAM-CMOS development.¹

Melbourne, Australia, 6 October 2026: dorsaVi Limited (ASX: DVL) ('dorsaVi' or 'the Company'), a leader in FDA cleared movement-sensor technology, is pleased to announce that it has, over the weekend, received firm commitments to raise \$3.0 million (before costs) through a placement of 136,363,636 fully paid ordinary shares ("New Shares") at an issue price of \$0.022 per share, from new and existing sophisticated, professional, and high net worth investors ("Placement").

Discussions with prospective robotics and defence partners have reinforced the Board's view that the value of dorsaVi's sensor business extends well beyond its established clinical, sport and workplace markets. Its core strength is capturing and interpreting high-fidelity, clinical-grade human movement data, an asset of growing scarcity for developers of humanoid robots and autonomous systems

¹ ASX Announcement 15 July 2026

dorsaVi's strategy comprises three connected verticals:

1. **Sensors and movement data:** wearable sensing, Video AI, biomechanics expertise and bespoke data capture, built on FDA-cleared and TGA-certified sensors deployed for more than a decade, with Sensor v6.5 launched last quarter²
2. **Intelligence layer:** the Company's licensed neuromorphic IP from Technion, to be expanded through selected compute-in-memory capabilities and future physical artificial neural network architectures.
3. **Semiconductors:** the RRAM development program with NTU and ITRI, targeting low-power, on-device intelligence. The first RRAM-CMOS validation chip has completed front-end and middle-of-line fabrication on TSMC's process, with RRAM integration and energy testing now under way³.

Those discussions have centered for smart-soldier systems, humanoid robotics, aerial drones and autonomous underwater vehicles, where clinical-grade human movement data and low-power, on-device intelligence are of particular interest. These are areas for targeted commercial and technical exploration rather than completed integrated products. The near-term focus for dorsaVi is to define customer requirements and convert these discussions into partner evaluations.

The Placement ensures dorsaVi is well-capitalised to accelerate all the aforementioned verticals.

Gernot Abl, Chairman of dorsaVi, commented:

"We thank our new and existing shareholders for their support of this Placement, and 62 Capital for its work on the raise.

Over the past year dorsaVi has laid the foundations of a Physical AI company. We have secured exclusive RRAM and robotics IP from NTU Singapore and neuromorphic IP from Technion, launched Sensor v6.5, and our first RRAM-CMOS chip is now in fabrication at TSMC. Our conversations with robotics and defence partners keep returning to the same point: a decade of clinical-grade human movement data, and the ability to capture more of it on demand, is a scarce asset.

This funding lets us act on that. We will expand our movement data and capture capability for humanoid robotics developers, and push our silicon program towards low-power, on-device intelligence. Our focus now is converting these discussions into evaluations and commercial outcomes."

Use of Proceeds

Proceeds from the Offer will be applied to accelerate dorsaVi's three-vertical strategy across sensors and movement data, the intelligence layer, and semiconductors, with a focus on humanoid robotics and defence. Specifically, funds will be used to expand dorsaVi's clinical-grade human movement data library and bespoke data-capture capability (wearable sensors and Video AI) to meet the requirements of humanoid robotics developers for balance, coordination and recovery data.

Funds will also target smart-soldier, aerial drone and autonomous underwater vehicle applications, and advance the Company's licensed neuromorphic IP and RRAM development program with NTU and ITRI toward low-power, on-device intelligence for systems operating under tight constraints on power, connectivity and size.

² ASX Announcement 28 July 2026

³ ASX Announcement 14 September 2026

The balance will fund partner evaluations, general working capital and the costs of the Offer.

Details of the Placement

Under the Placement the Company will issue a total of 136,363,636 New Shares at an issue price of \$0.022 per under the Company's existing ASX Listing Rule 7.1 (13,363,636 New Shares) and 7.1A placement (123,300,000 New Shares) capacities. In addition, 68,181,818 free attaching Unlisted Options, on a 1 for 2 basis, with an exercise price of \$0.045 and expiring 3 years from the date of issue ("Placement Options"), will be issued in accordance with the Company's placement capacity in accordance with ASX Listing Rule 7.1.

The offer price of \$0.022 per new share represents a:

- 12% discount to the last traded price of \$0.025 per share on 1 October 2026, being the last date that the Company's shares traded on the ASX prior to the date of this announcement;
- 15% discount to the 10-day VWAP of \$0.026 per share up to and including 1 October 2026; and
- 8% discount to the 15-Day VWAP of \$0.024 per share up to and including 1 October 2026.

The Placement was led by 62 Capital. 62 Capital will receive a fee of 6% of the gross amount raised, together with 24,000,000 unlisted options exercisable at \$0.045 per option on or before the date that is 3 years from the date the options (Broker Options) are issued for services provided as lead manager. The Broker Options will be issued in accordance with the Company's placement capacity under ASX Listing Rule 7.1.

Settlement of the New Shares is expected to occur on or around Monday 19 October 2026.

- ENDS -

This release has been authorised for lodgement to the ASX by the Board.

Mathew Regan Group Chief Executive Officer +61 427 477 298 Email: mregan@dorsaVi.com	Gernot Abl Chairman +61 419 802 653 Email: ga@dorsaVi.com
---	--

Forward-Looking Statements

This announcement may contain certain forward-looking statements and projections. Such forward-looking statements/projections are estimates for discussion purposes only and should not be relied upon. Forward looking statements/projections are inherently uncertain and may therefore differ materially from results ultimately achieved. dorsaVi Limited does not make any representations and provides no warranties concerning the accuracy of the projections and disclaims any obligation to update or revise any forward-looking statements/projections based on new information, future events or otherwise, except to the extent required by applicable laws.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on delivering intelligence at the ultra-edge. Enabling real time AI-driven decisions to be made locally, at the point of sensing, without reliance on cloud connectivity. dorsaVi's wearable sensor technology captures, quantifies, and assesses detailed human movement and position outside a biomechanics lab, in both real-time and real situations for up to 24 hours, across clinical applications, elite sports, and occupational health and safety. Underpinning this vision, dorsaVi is building the hardware foundations of the ultra-edge through strategic investments in neuromorphic computing and RRAM memory technology. dorsaVi's focus is on three major markets:

- **Ultra-Edge Intelligence:** dorsaVi's sensor platforms are designed to process and act on data locally, embedding AI-driven inference directly at the point of capture. By investing in neuromorphic computing and RRAM memory technology, dorsaVi enables real-time decision-making without round-tripping to the cloud, delivering lower latency, lower power consumption, and reliable operation in latency- and connectivity-constrained environments across industrial, clinical, and autonomous systems applications.
- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com